Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
Hennepin Healthcare Research Institute
Study ID
NCT06514547
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Conjugate Pneumococcal Vaccine 20 (PCV20) — BIOLOGICAL
    Vaccine

Study Details

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

Key Dates

Start date
Jul 8, 2024
Status verified
Jun 2025
Primary completion
Sep 15, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
250 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Pneumococcal Vaccination
    All participants will receive a pneumococcal vaccine.

Primary Outcome Measure

Primary objective [ Time Frame: 30 days and 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Hennepin Healthcare SystemMinneapolisMinnesota55415
Anne Frosch, MD

Find similar trials in Minneapolis, MN

By condition
HIV
By specialty
Infectious disease
By research site
Hennepin Healthcare System· Minneapolis, MN

Related Studies